Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors Journal Article


Authors: Seidman, A. D.; Scher, H. I.; Heinemann, M. H.; Bajorin, D. F.; Sternberg, C. N.; Dershaw, D. D.; Silverberg, M.; Bosl, G. J.
Article Title: Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors
Abstract: A Phase I‐II trial of gallium nitrate was conducted in 40 patients with bidimensionally measurable urothelial tract tumors who had failed to respond to combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin. Partial responses were observed in 4 of 23 patients (17.4%) who received 350 mg/m2/d or more for 5 days by continuous intravenous infusion. In two additional patients who received 350 mg/m2/d or more, a minor response and a mixed response were observed. The median duration of response was 4 months (range, 2 to 8 months). A dose–response relationship was suggested because no responses were observed in 17 patients who received less than 350 mg/m2/d. Myelosuppression was minimal. The dose‐limiting toxic reaction was a reversible optic neuropathy that occurred in 3 of 11 patients who received 400 mg/m2/d. Further evaluation of infusional gallium nitrate is warranted in patients with urothelial tract malignant tumors. Cancer 68:2561–2565, 1991. Copyright © 1991 American Cancer Society
Keywords: adult; clinical article; treatment outcome; aged; aged, 80 and over; cisplatin; doxorubicin; antineoplastic agents; methotrexate; phase 2 clinical trial; bone marrow suppression; neuropathy; vinblastine; urothelium; bladder neoplasms; eye disease; phase 1 clinical trial; carcinoma, transitional cell; transitional cell carcinoma; intravenous drug administration; middle age; gallium; drug evaluation; gallium nitrate; human; male; female; priority journal; article; support, u.s. gov't, p.h.s.
Journal Title: Cancer
Volume: 68
Issue: 12
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 1991-12-15
Start Page: 2561
End Page: 2565
Language: English
DOI: 10.1002/1097-0142(19911215)68:12<2561::Aid-cncr2820681205>3.0.Co;2-g
PUBMED: 1933802
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 27 September 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. D David Dershaw
    223 Dershaw
  2. Dean Bajorin
    657 Bajorin
  3. Andrew D Seidman
    318 Seidman
  4. Howard Scher
    1130 Scher
  5. George Bosl
    430 Bosl